Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. (ParvOryx01)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01301430 |
Recruitment Status :
Completed
First Posted : February 23, 2011
Last Update Posted : November 21, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Glioblastoma Multiforme | Drug: H-1PV | Phase 1 Phase 2 |
Investigation on safety, tolerability and efficacy of H-1 parvovirus (H-1PV) in subjects suffering from glioblastoma multiforme.
H-1PV will primarily be administered either intratumoral or intravenously. Ten days thereafter a complete or a subtotal tumor resection with a subsequent administration of H-1PV into the walls of the resection cavity will be carried out.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 18 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. |
Study Start Date : | September 2011 |
Actual Primary Completion Date : | May 2015 |
Actual Study Completion Date : | May 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: H-1 parvovirus (H-1PV) |
Drug: H-1PV
H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).
Other Name: ParvOryx (brand name of H-1PV) |
- Safety and tolerability [ Time Frame: Up to 28 days after the first administration of the IMP ]
Parameters for assessment of safety and tolerability:
- physical/neurological examinations (pathological findings as quality and quantity)
- adverse events (quality and quantity per dose level)
- vital signs, ECG, laboratory parameters (pathological findings as quality and quantity, for laboratory parameters: descriptive statistics)
- viral shedding and viral specific antibodies (quantity depicted over time)
- Efficacy (treatment response) [ Time Frame: Up to 6 months after the first administration of the IMP ]
Parameters for evaluation of efficacy:
- Progression free survival (PFS) based on modified RECIST-criteria depicted as Kaplan-Meier curve
- Overall survival (OS) depicted as Kaplan-Meier curve

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age over or equal to 18 years old,
- Diagnosis of glioblastoma multiforme,
- Written informed consent,
- Recurrent or progressive disease despite previous radio- and/or chemotherapy,
- Indication for complete or subtotal tumor resection,
- Life expectancy of at least 3 months,
- Consent for sampling and investigation of biological specimens,
- Karnofsky Performance Score over or equal to 60,
- Adequate seizure control,
- Adequate bone marrow function: neutrophils > 1.5 x 10exp9/L, platelets > 100 x 10exp9/L, hemoglobin > 9.0 g/dL,
- Adequate liver function: Bilirubin < 2.0 g/dL, ASAT, ALAT, AP, GGT < 3 x ULN,
- Adequate renal function: Creatinine < 1.8 g/dL,
- Adequate blood clotting: aPTT < 35 sec, INR < 1.2,
- Negative serology for HIV, HBV and HCV,
- Negative Beta-HCG test in women of childbearing potential,
- Commitment to use adequate contraception (in both genders) for up to six months after study entry,
- Commitment to omit exposure to infants < 18 months of age or immunocompromised individuals for up to 28 day after first administration of IMP.
Exclusion Criteria:
- Multifocal disease,
- Evidence of distant tumor metastases,
- Contraindications for MRI,
- Active infection within 5 days prior to the study inclusion,
- Chemotherapy within 4 weeks prior to the study inclusion,
- Radiotherapy within 6 weeks prior to the study inclusion,
- Participation in another interventional trial within the last 30 days,
- Treatment with antiangiogenic substances within 21 days prior to therapy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01301430
Germany | |
Department of Neurosurgery, University Hospital Heidelberg | |
Heidelberg, Germany, 69120 |
Principal Investigator: | Andreas Unterberg, Prof. Dr. | Department of Neurosurgery, University Hospital Heidelberg | |
Study Director: | Bernard Huber, Dr. | Oryx GmbH & Co. KG |
Responsible Party: | Oryx GmbH & Co. KG |
ClinicalTrials.gov Identifier: | NCT01301430 |
Other Study ID Numbers: |
ParvOryx01 |
First Posted: | February 23, 2011 Key Record Dates |
Last Update Posted: | November 21, 2022 |
Last Verified: | March 2015 |
Progressive glioblastoma multiforme Recurrent glioblastoma multiforme Oncolytic virus |
Glioblastoma Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors |
Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |